CLSD - Clearside Biomedical - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CLSD is currently covered by 5 analysts with an average price target of $6.83. This is a potential upside of $5.95 (676.14%) from yesterday's end of day stock price of $0.88.

Clearside Biomedical's activity chart (see below) currently has 46 price targets and 69 ratings on display. The stock rating distribution of CLSD is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 6.94% with an average time for these price targets to be met of 101.63 days.

Highest price target for CLSD is $6, Lowest price target is $5, average price target is $5.2.

Most recent stock forecast was given by SERGE BELANGER from NEEDHAM on 06-Mar-2025. First documented stock forecast 15-Aug-2016.

Currently out of the existing stock ratings of CLSD, 21 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$6

$4.99 (494.06%)

2 months 10 days ago
(06-Mar-2025)

0/12 (0%)

$5.15 (605.88%)

Buy

$6

$4.99 (494.06%)

2 months 10 days ago
(06-Mar-2025)

0/9 (0%)

$5.15 (605.88%)

Buy

$5

$3.99 (395.05%)

$4

10 months 21 days ago
(25-Jun-2024)

0/2 (0%)

$3.75 (300.00%)

Buy

$5

$3.99 (395.05%)

$5

1 years 2 months 3 days ago
(13-Mar-2024)

0/5 (0%)

$3.37 (206.75%)

Buy

$4

$2.99 (296.04%)

$19

1 years 2 months 3 days ago
(13-Mar-2024)

2/9 (22.22%)

$2.37 (145.40%)

327

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CLSD (Clearside Biomedical) average time for price targets to be met?

On average it took 101.63 days on average for the stock forecasts to be realized with a an average price target met ratio 6.94

Which analyst has the current highest performing score on CLSD (Clearside Biomedical) with a proven track record?

LIANA MOUSSATOS

Which analyst has the current lower performing score on CLSD (Clearside Biomedical) with a proven track record?

ANDREAS ARGYRIDES

Which analyst has the most public recommendations on CLSD (Clearside Biomedical)?

Liana Moussatos works at WEDBUSH and has 10 price targets and 7 ratings on CLSD

Which analyst is the currently most bullish on CLSD (Clearside Biomedical)?

Zegbeh Jallah with highest potential upside - $13.99

Which analyst is the currently most reserved on CLSD (Clearside Biomedical)?

Annabel Samimy with lowest potential downside - -$0

Clearside Biomedical in the News

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that six presentations related to the Company’s lead program, CLS-AX (axitinib injectable suspension), and suprachoroidal drug delivery platform...

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?